Chapters

Transcript

Video

What is your guidance about when to integrate tests for circulating tumor DNA (ctDNA) into protocols for precision cancer medicine? How does this test compare to tissue-based NGS?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Samuel Klempner, MD

Samuel Klempner, MD

Director of Precision Medicine
The Angeles Clinic and Research Institute
Cedars-Sinai Medical Center
Los Angeles, CA